Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - October 2015

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for October 2015 (PDF).

Clinicians are advised that mirebegron (Betmiga®) is now contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both) following an EU-wide review of the latest safety data. It is also recommended that blood pressure should be measured before starting treatment and monitored regularly during treatment, especially in patients with hypertension.

It is also noted in this edition that a letter informing of a risk of severe hypertension and associated cerebrovascular and cardiac events linked with mirebegron use was sent to healthcare professionals in September.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - October 2015' on Email Share 'Drug Safety Update - October 2015' on Delicious Share 'Drug Safety Update - October 2015' on Digg Share 'Drug Safety Update - October 2015' on Facebook Share 'Drug Safety Update - October 2015' on Google+ Share 'Drug Safety Update - October 2015' on reddit Share 'Drug Safety Update - October 2015' on StumbleUpon Share 'Drug Safety Update - October 2015' on Twitter

atomic-wealth

No Comments to “Drug Safety Update - October 2015”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,083 spam comments.

atomic-wealth
fond-illness
summer